Ocuphire Pharma Inc OCUP

NAS: OCUP | ISIN: US67577R1023 14/11/2024

1,060 USD (-2,75%)

(-2,75%) 14/11/2024

Toon enkel gratis nieuws

27 september 2023 · Viatris and Ocuphire Pharma Announce FDA Approval of RYZUMVl™ (Phentolamine Ophthalmic Solution) 0.75% Eye Drops for the Treatment of Pharmacologically-Induced Mydriasis Produced by Adrenergic Agonists (e.g., Phenylephrine) or Parasympatholytic (e.g., Tropicamide) Agents · Persbericht

15 maart 2021 · Ocuphire Announces MIRA-2 Phase 3 Registration Trial for the Reversal of Mydriasis Meets Primary Endpoint · Persbericht

10 maart 2021 · Ocuphire Announces Financial Results for the Full Year 2020 and Provides Corporate Update · Persbericht

5 maart 2021 · Ocuphire Announces Publication of MIRA-1 Phase 2b Results in Optometry and Visual Science Demonstrating Reduction of Pharmacologically Induced Mydriasis by Nyxol® · Persbericht

18 februari 2021 · Ocuphire Initiates Enrollment in VEGA-1 Phase 2 Trial Investigating Nyxol in Presbyopia · Persbericht

11 februari 2021 · Ocuphire to Participate in the 2021 BIO CEO & Investor Conference and Cantor Fitzgerald’s Panel on Eyeing Key Events in the Ophthalmology Space in 2021 · Persbericht

20 januari 2021 · Ocuphire Announces Publication of ORION-1 Phase 2 Results for Nyxol in Clinical Ophthalmology and Presentation at the January OIS Presbyopia Innovation Showcase · Persbericht

Mijn selecties

Je selectie is nog leeg.

Voeg nu effecten toe